University of Michigan/Rogel Cancer Center
Ann Arbor, Michigan
Francis Paul Worden, MD
Dr Frank Worden earned his medical degree from the Indiana University School of Medicine, and he completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center before pursuing a fellowship in adult hematology and oncology at the University of Michigan. He is a clinical professor medicine, practicing oncology at the Rogel Cancer Center, and he specializes in the treatment of head and neck and thyroid malignancies. He is the co-chair of the Head and Neck and Endocrine Cancers Clinical Research Team. Since joining the faculty in 2000, Dr Worden has conducted a robust clinical trial program in which he has written, conducted, and published on the outcomes of various head and neck and thyroid cancer clinical trials. In 2009, he became the hematology and oncology fellowship program director, and in 2020, he was named the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Dr. Worden has contributed to the publications of landmark clinical trials in the Lancet and the New England Journal of Medicine that have ultimately led to the FDA approval of two small molecule inhibitors to treat metastatic iodine-refractory and medullary thyroid cancers.
Bristol-Myers Squibb, Lilly Pharmaceuticals, Merck (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Consultant, Grant/Research Support
Friday, March 18, 2022
9:00 AM – 10:45 AM
Friday, March 18, 2022
9:45 AM – 10:10 AM
Friday, March 18, 2022
11:45 AM – 1:10 PM
Friday, March 18, 2022
12:30 PM – 12:50 PM
Friday, March 18, 2022
12:50 PM – 1:10 PM